UMass team nabs $17M from NIAID to produce HIV vaccine


As HIV researchers around the globe work to advance vaccines against the devastating virus, the NIAID has awarded $17.3 million to the University of Massachusetts Medical School’s Dr. Shan Lu and colleagues to develop and manufacture a prime-boost candidate for a midstage trial.

As part of a program spanning 7 years, Lu’s team will work to create a manufacturing process for the experimental vaccine intended to produce doses for several hundred volunteers in a Phase II trial, according to the school’s release. If successful, the team could seek to leverage that progress for a Phase III trial ranging in the thousands of doses.

After two decades in HIV research, Lu said in a statement the manufacturing validation program is the “next stage” for the vaccine candidate. The team has “made incredible progress in developing a cocktail of antigens capable of producing antibodies using our ‘prime-boost’ method,” he said.

Whitepaper Download

Reducing the Complexity and Costs of Channel Planning and Logistics

How can you make the process of bringing your product to market less complex while also reducing costs? This Whitepaper identifies opportunities to simplify channel strategies for biopharma companies, their customers and patients. Discover how you can deliver savings and innovation to your business.

The funding comes during a busy year in HIV vaccine research and on the heels of an announcement by the NIH that it’s launching a large-scale Phase IIb/III HIV vaccine trial in South Africa later this year. That study will test HVTN 100--made up of one experimental vaccine each supplied by Sanofi Pasteur and GlaxoSmithKline ($GSK)--in 5,400 HIV-uninfected men and women with 5 injections over one year.

Aside from the NIH, players large and small have committed to the effort over the past year; Aelix Therapeutics launched with $12.7 million in January and the European Commission before that committed €23 million to a public-private partnership of 22 institutions.

For their approach, Lu and colleagues joined an in-house DNA vaccine with a recombinant protein-based vaccine. They’re expecting to further revamp the shot, according to a statement, and will work with clinical supply manufacturer Waisman Biomanufacturing on the next steps.

- here’s the release

Related Articles:
NIH to launch large-scale HIV vaccine trial in South Africa
European Commission launches €23M HIV vaccine research initiative
New HIV vaccine player Aelix Therapeutics hits the scene with $12.7M Series A


Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.